Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
AssigneeUniversity of South Florida
InventorsJin Q. Cheng, Said M. Sebti
Life of this patent
Estimating the term…
Abstract
This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
Claims23
A method for treating breast cancer in a patient in need thereof comprising administering to said patient a therapeutically effective amount of triciribine (TCN), triciribine-phosphate phosphate (TCN P), derivatives of TCN or a related compound or pharmaceutically acceptable salts thereof in combination or alternation with at least one additional chemotherapeutic agent.
A method for identifying and treating a patient having a breast cancer tumor or a cell with enhanced sensitivity to triciribine (TCN) comprising the steps of:
- (a) determining whether the patient has a tumor or a cancer cell with enhanced sensitivity to TCN by:
- (i) obtaining a biological sample of the breast tumor or cell from the patient;
- (ii) measuring the expression level of AKT kinase of the sample;
- (iii) comparing the expression level of AKT kinase of the sample to the expression level in a control tissue wherein a 1.5 greater fold expression of Akt in the sample compared to the control tissue is indicative of a patient having a tumor or cancer cell with enhanced sensitivity to TCN;
- and
- (b) if the sample has enhanced sensitivity to TCN, administering to the patient TCN, TCN P, derivatives of TCN or a related compound or pharmaceutically acceptable salts thereof in combination or alternation with at least one additional chemotherapeutic agent.
Dependencies are inferred from the claim text.